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Bernard Cazelles and colleagues 
looked at the details of the relationship 
between dengue incidence and El 
Niño in Thailand. Their results, based 
on complex mathematical analysis, do 
not provide easy answers for those who 
might want to plan for dengue outbreaks, 
though they do go some way to helping 
to understand the complex interplay 
between the various factors. In essence, 
the researchers found that there was a 
signiﬁ  cant association between El Niño 
oscillations, climate variables, and dengue 
hemorrhagic fever incidence with a 
2- to 3-year repeat, for both Bangkok 
and the rest of Thailand. However this 
association was signiﬁ  cant only for the 
years 1986–1992, and outside these years 
factors other than climate were probably 
responsible for triggering the disease 
outbreaks.
Cazelles B, Chavez M, McMichael AJ, Hales 
S (2005) Nonstationary inﬂ  uence of El 
Niño on the synchronous dengue epidemics 
in Thailand. DOI: 10.1371/journal.
pmed.0020106
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Compared with malaria, dengue 
fever has a rather lower proﬁ  le in the 
public mind, although to those who 
have had it, it leaves a great impression. 
The name dengue fever is derived from 
the Swahiliwords Ki denga pepo (“it is 
a sudden overtaking by an evil spirit”), 
which gives an idea of the rapid onset of 
the disease. The dengue virus is carried 
by the mosquito Aedes aegypti, and 
the disease often occurs as epidemics. 
Although the classic illness is a fairly 
benign acute febrile syndrome, it may 
be very painful—hence the English 
nickname, breakbone fever. The virus 
can also cause a much more serious 
illness known as dengue hemorrhagic 
fever, which can progress to dengue 
shock syndrome. There are four main 
serotypes of the dengue RNA virus; 
dengue hemorrhagic fever is more likely 
to occur during dengue infection in 
people with preexisting active or passive 
(e.g., maternally acquired) immunity 
who are exposed to a different dengue 
virus serotype. In contrast to classic 
dengue, the hemorrhagic fever and 
shock syndromes are mostly diseases 
of children and, if untreated, have a 
mortality of around 50%.
Around two-ﬁ  fths of the world’s 
population are now at risk of the disease 
(one estimate is that 80 million people 
are infected each year). The number at 
risk will increase as population growth, 
urbanization, international travel, and 
climate change inﬂ  uence transmission 
of the disease. Understanding how all 
these factors interact is important in 
planning for disease outbreaks. However, 
the incidence of dengue is not easily 
predictable, varying with season, and also 
between years. For example, although 
dengue is most prevalent in the wet 
season, dengue epidemics have also 
been associated with drought in some 
countries. El Niño is the best known 
climatic event affecting climate between 
years, and some research already 
suggests that there is a relationship 
between the timing of dengue epidemics 
and El Niño in the Paciﬁ  c Islands and in 
other countries. 
Previous research has uncovered 
traveling waves of dengue in Thailand, 
but the cause of these has been obscure. 
In a paper in this month’s PLoS Medicine 
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Aedes aegypti, the main vector of dengue 
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Before insulin was discovered and 
puriﬁ  ed, doctors could only watch as 
their patients slowly died of type 1 
diabetes mellitus. In January 1922, the 
prognosis was changed dramatically 
when a teenager with diabetes in a 
Toronto hospital became the ﬁ  rst 
recorded recipient of an injection of 
insulin. Although this preparation was 
far from perfect, as Frederick Banting 
said in his Nobel lecture of 1925 (Nobel 
laureates did not have to wait so long 
as they do now for recognition), “There 
was a marked reduction in blood sugar 
and the urine was rendered sugar free.” 
Suddenly diabetes was a potentially 
curable disease. But insulin’s very success 
brought trouble, as demand far exceeded 
the supply. 
Now recombinant insulin is available 
in plentiful supply, but the control of 
type 1 diabetes remains far from perfect, 
and researchers have looked towards an 
ideal of transplanting insulin-producing 
cells instead. The best protocol for this, 
also pioneered in Canada, the Edmonton 
protocol, uses β-cells isolated from 
human cadavers and has shown some 
remarkable results with around 84% of 
patients remaining insulin-free after one 
year and 89% of patients still producing 
insulin after three years. However, the 
isolation of β-cells is laborious and 
limited by donor availability.
The next logical step, then, is to 
look for renewable sources of insulin-
producing cells. The emerging science 
of human stem cell research makes 
this step possible, and in a paper in this 
month’s PLoS Medicine Seung Kim and 
colleagues from Stanford University 
suggest that researchers should look 
beyond just pancreatic precursors and 
embryonic stem cells to other cell-
type precursors for ideas about β-cell 
replacement. 
The rationale for the approach in 
this study comes from observations 
that although the pancreatic islet cells 
are the principal source of insulin in 
humans, in some invertebrate species, 
such as Drosophila, most circulating 
insulin is produced by brain neurons. 
Intriguingly, the gene encoding insulin 
is also transcribed by some vertebrate 
neurons—although it is not clear 
whether they then produce or secrete 
insulin protein. 
Kim and colleagues took human neural 
progenitor cells derived from brain, 
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Hypertension is common in afﬂ  uent 
societies and a major risk factor for heart 
disease. In Canada, hypertension is the 
leading primary diagnosis for patient 
visits to physicians’ ofﬁ  ces. Beyond 
recommending lifestyle changes such 
as losing weight, quitting smoking, 
and lowering salt and alcohol intake, 
prescription drugs are indicated in 
many patients. As a consequence, 
antihypertensive drugs are the leading 
category of prescription drugs in Canada, 
accounting for 20% of prescription drug 
sales. 
Several classes of drugs are available 
for treatment, including diuretics, ACE 
inhibitors, and calcium channel blockers. 
First-line treatment with thiazide 
diuretics—the oldest and by far the 
cheapest drug class—has been shown 
in randomized trials to reduce serious 
cardiovascular morbidity and mortality 
with beneﬁ  ts at least as great as ﬁ  rst-line 
treatment with other drug classes. 
Steve Morgan and colleagues set 
out to examine whether prescribing 
practices were in accordance with this 
evidence. They analyzed administrative 
claims data from a public drug plan 
for seniors (residents of age 65 and 
older) to determine trends in ﬁ  rst-line 
hypertension drug use. During the 
period from 1993 to 2000, over 82,000 
seniors were identiﬁ  ed as new users of 
hypertension drugs. Less than a third of 
these patients received thiazides (alone 
or as part of a combination regimen) as a 
ﬁ  rst-line treatment. 
The share of new patients receiving 
a thiazide increased over the study 
period, but did not exceed 45% at any 
point. Women were more likely than 
men, and older patients were more likely 
than younger ones, to receive thiazides. 
Comorbidities also inﬂ  uenced prescribing 
practices: patients without concurrent 
diagnoses were more likely to receive 
thiazides. While for some comorbidities 
(such as previous acute myocardial 
infarction) evidence suggested that there 
were good reasons to prescribe drugs 
other than thiazides, no such evidence 
existed for many of the other conditions 
that nevertheless were associated with 
lower prescription of thiazides. 
Changes in drug availability and 
existing evidence during the period 
studied make it difﬁ  cult to calculate the 
exact extent to which thiazides were 
under-prescribed. However, the study 
shows that many patients received 
drugs that had previously been found 
to be no better at treating hypertension 
than much cheaper alternatives. Drug 
prices changed over the study period 
as well, but even comparing the 
lowest price for any of the alternatives 
to thiazides, $0.34 per day, with the 
constant cost of less than $ 0.01 per day 
for a thiazide makes it clear that a lot of 
money was wasted. 
On a more positive note, prescription 
of thiazides as a ﬁ  rst-line therapy rose 
over the study period—from 25% to 
42% in patients without comorbidities. 
Most of the increase occurred shortly 
after a speciﬁ  c local education 
campaign. This suggests that repeated 
targeting of prescribing physicians—
many of whom receive regular 
marketing material from pharmaceutical 
companies and subscribe to the general 
view that newer drugs are better—with 
current evidence-based information 
should be considered. 
One of the most inﬂ  uential studies 
comparing antihypertensive drugs, the 
ALLHAT study, also supported the use 
of thiazides as ﬁ  rst-line drugs. ALLHAT 
was published in 2003, and its results 
widely publicized. According to Steve 
Morgan, “Anecdotal evidence suggests 
that ALLHAT has had an inﬂ  uence on 
prescription practices, but I am not aware 
of a large-scale analysis yet.”
Morgan S, Bassett KL, Wright JM, Yan L 
(2005) First-line ﬁ  rst? Trends in thiazide 
prescribing for hypertensive seniors. DOI: 
10.1371/journal.pmed.0020080
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and exposed them to a series of signals 
that are known to drive pancreatic 
islet development. They were able to 
produce clusters of insulin-producing 
cells that were responsive to glucose 
in vitro. After transplantation into 
immunocompromised mice, circulating 
human insulin and C-peptide derived 
from the proinsulin precursor were 
detected when the mice were given 
glucose.
Of course, results in mice do not mean 
that such treatments would automatically 
work in humans, and before any such 
therapies become available there are 
many hurdles to overcome. Some of the 
most important include the long-term 
stability and safety of the cells (although 
the cells remained differentiated in the 
mice and did not form tumors, such a 
risk would need to be very thoroughly 
investigated because of the chronic 
nature of diabetes), and how to scale 
up such a process to produce the much 
larger numbers of cells needed for 
human treatment. Nonetheless, work like 
this study from Kim’s group might point 
to where the future of diabetes treatment 
lies.
Hori Y, Gu X, Xie X, Kim SK (2005) 
Differentiation of insulin-producing cells 
from human neural progenitor cells. DOI: 
10.1371/journal.pmed.0020103
DOI: 10.1371/journal.pmed.0020115.g001
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There are 300 million cases of malaria 
each year worldwide, causing one million 
deaths. Around 90% of these deaths 
occur in Africa, mostly in young children. 
One of the greatest challenges facing 
Africa in the ﬁ  ght against malaria is drug 
resistance; resistance to chloroquine 
(CQ), the cheapest and most widely used 
antimalarial, is common throughout 
Africa, and resistance to sulfadoxine-
pyrimethamine (SP), the ﬁ  rst-developed 
and least expensive alternative to CQ, is 
also increasing in eastern and southern 
Africa. These trends have forced many 
countries to change their treatment 
policies and use more expensive drugs, 
including drug combinations that will 
hopefully slow the development of 
resistance. One avenue of research is 
to identify combinations that minimize 
gametocyte emergence in treated cases 
and prevent selective transmission of 
parasites resistant to any of the partner 
drugs. 
In this month’s PLoS Medicine Colin 
Sutherland and colleagues tested 
two leading combination therapies in 
children with uncomplicated malaria. 
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Thick blood ﬁ  lms from patients in Gambia 
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As the HIV-1 epidemic continues to grow, mutations in the 
virus that confer drug resistance are becoming increasingly 
important in the clinical management of patients worldwide. 
Of all the different virus subtypes (A, B, C, D, F, G, H, J, and K) 
and a rapidly increasing number of established and emerging 
recombinant viruses, it is subtype B that predominates 
in Western Europe, the United States, and the rest of the 
industrialized world. Antiretroviral drugs were 
developed by studying subtype B, and most 
data on the genetic mechanisms of HIV 
drug resistance are also from subtype 
B. However, worldwide, subtype B 
is in the minority (~10% of the 
infected population). In Africa, for 
example, where there is broad 
viral diversity, there is a greater 
spread of subtypes, with 
subtype C being the most 
common, representing over 
half of all infections. Although 
it seems that current drugs—
developed against subtype 
B virus—are active against 
non-subtype-B virus, one 
critical issue is whether viruses 
from some subtypes or particular 
regions are more likely than 
others to develop resistance against 
certain drugs. Another crucial issue is 
to identify the mutations that confer 
drug resistance in non-B subtypes. 
Answering these questions might 
determine whether initial treatment 
strategies should be different for 
people with non-subtype-B viruses, and also could help decide 
how patients with non-subtype-B virus who fail antiretroviral 
therapy should be managed.
In a paper in this month’s PLoS Medicine, Rami Kantor and 
colleagues from a worldwide collaboration have looked at the 
mutations found in 3,686 people with non-subtype-B HIV-1 
infections compared with those in 4,769 people with subtype B 
infections. They wanted to answer two questions: ﬁ  rst, whether 
the mutations that cause drug resistance in subtype B viruses 
also develop in non-subtype-B viruses exposed to antiretroviral 
drugs, and second, whether novel mutations (i.e., not previously 
seen in subtype B virus) develop in non-subtype-B viruses when 
they fail to respond to antiretroviral drugs. What they found was 
that all of the 55 drug-resistance mutations that 
have been known to occur in subtype B also 
occurred in at least one non-subtype-B 
isolate, and most of these mutations 
were also statistically associated with 
antiretroviral treatment in at least 
one non-B subtype. Conversely, 
of the 67 mutations associated 
with antiretroviral therapy in 
at least one non-B subtype, 
61 were also associated with 
antiretroviral therapy in 
subtype B isolates. 
So it appears that few 
novel mutations are arising 
in non-subtype-B viruses 
exposed to the current 
antiretroviral drugs and that 
the present focus on subtype B 
mutations for global surveillance 
and genotypic assessments of drug 
resistance is a reasonable approach. 
However, the authors emphasize that 
differences in the types and patterns of 
drug-resistance mutations are likely to 
differ between the subtypes, and that 
larger numbers of samples and further 
analyses are needed to exclude the possibility of new and/or rare 
subtype-speciﬁ  c mutations.
Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et 
al. (2005) Impact of HIV-1 subtype and antiretroviral therapy on 
protease and reverse transcriptase genotype: Results of a global 
collaboration. DOI: 10.1371/journal.pmed.0020112
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One regimen was an artemisinin-based 
combination consisting of artemether 
and lumefantrine (co-artemether, 
trade names CoArtem and Riamet). 
The other was a combination of CQ 
and SP—currently under consideration 
in several African countries, largely 
due to its low cost. In this randomized, 
controlled trial, 497 children with acute 
uncomplicated falciparum malaria were 
given either a combination of CQ and 
SP or six doses of co-artemether (91 
received CQ/SP and 406 received co-
artemether), and their blood was tested 
for infectivity to mosquitoes seven 
days after treatment. During follow 
up at seven, 14, and 28 days the team 
found that children treated with co-
artemether were signiﬁ  cantly less likely 
to carry gametocytes in their blood than 
children treated with CQ and SP—7.9% 
compared with 48.8%. 
Altogether, the six-dose regimen of 
co-artemether was highly effective at 
reducing the prevalence and duration 
of gametocyte carriage. The numbers of 
gametocytes and the infectiousness to 
mosquitoes at day 7 were also reduced 
compared to a combination of CQ and 
SP, said the authors. Other studies have 
already shown the potential of co-
artemether combination therapy to both 
cure malaria and reduce gametocyte 
carriage, acknowledged the authors. 
However, this study is the ﬁ  rst to 
demonstrate the treatment’s potential 
to markedly reduce the infectiousness 
of patients to mosquitoes, and has done 
so in a sub-Saharan African setting with 
highly seasonal transmission and where 
asymptomatic infections are common. 
Do the results mean co-artemether 
should be introduced as a ﬁ  rst-line 
treatment for malaria in Africa? The 
authors are hesitant and suggest there 
might be compliance issues with the 
six-dose regimen. The requirement of 
oily food for adequate absorption might 
also lead to inadequate drug levels in the 
blood of many treated individuals. 
The authors suggest that co-
artemether as a ﬁ  rst-line treatment is 
not likely to reduce overall transmission 
of Plasmodium falciparum within the 
community but rather would reduce 
selective transmission of resistant 
parasites in treated patients. Hence, co-
artemether could have a public health 
beneﬁ  t by reducing the impact of drug 
resistance. 
Sutherland CJ, Ord R, Dunyo S, Jawara 
M, Drakeley CJ, et al. (2005) Reduction 
of malaria transmission to Anopheles 
mosquitoes with a six-dose regimen of 
co-artemether. DOI: 10.1371/journal.
pmed.0020092
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